Eurobio Scientific SA
Eurobio Scientific SA Fundamental Analysis
Eurobio Scientific SA (ALERS.PA) shows weak financial fundamentals with a PE ratio of 96.04, profit margin of 1.47%, and ROE of 1.33%. The company generates $0.2B in annual revenue with strong year-over-year growth of 18.60%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 51.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ALERS.PA's fundamental strength across five key dimensions:
Efficiency Score
WeakALERS.PA struggles to generate sufficient returns from assets.
Valuation Score
ModerateALERS.PA shows balanced valuation metrics.
Growth Score
ModerateALERS.PA shows steady but slowing expansion.
Financial Health Score
ExcellentALERS.PA maintains a strong and stable balance sheet.
Profitability Score
ModerateALERS.PA maintains healthy but balanced margins.
Key Financial Metrics
Is ALERS.PA Expensive or Cheap?
P/E Ratio
ALERS.PA trades at 96.04 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ALERS.PA's PEG of -2.26 indicates potential undervaluation.
Price to Book
The market values Eurobio Scientific SA at 1.28 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 12.41 times EBITDA. This signals the market has high growth expectations.
How Well Does ALERS.PA Make Money?
Net Profit Margin
For every $100 in sales, Eurobio Scientific SA keeps $1.47 as profit after all expenses.
Operating Margin
Core operations generate 8.87 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.33 in profit for every $100 of shareholder equity.
ROA
Eurobio Scientific SA generates $0.93 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Eurobio Scientific SA generates limited operating cash flow of $8.83M, signaling weaker underlying cash strength.
Free Cash Flow
Eurobio Scientific SA produces free cash flow of $7.33M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.73 in free cash annually.
FCF Yield
ALERS.PA converts 3.29% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
96.04
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-2.26
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.28
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.39
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.68
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.009
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How ALERS.PA Stacks Against Its Sector Peers
| Metric | ALERS.PA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 96.04 | 28.54 | Worse (Expensive) |
| ROE | 1.33% | 738.00% | Weak |
| Net Margin | 1.47% | -43982.00% (disorted) | Weak |
| Debt/Equity | 0.11 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.68 | 2806.01 | Strong Liquidity |
| ROA | 0.93% | -14624.00% (disorted) | Weak |
ALERS.PA outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Eurobio Scientific SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
177.30%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
35.03%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
256.28%
Industry Style: Defensive, Growth, Innovation
High Growth